Glenmark’s Remogliflozin Hopes To Shake Up Indian SGLT2i Market

 
• By Anju Ghangurde
Diabetes
GLENMARK HAS LAUNCHED A NOVEL SGLT2 Inhibitor

More from India

More from Focus On Asia